Results 41 to 50 of about 30,994 (308)

The Role of GIP Receptor in the CNS for the Pathogenesis of Obesity

Diabetes, 2021
Glucose-dependent insulinotropic polypeptide (GIP) (also known as gastric inhibitory polypeptide) is a hormone produced in the upper gut and secreted to the circulation in response to the ingestion of foods, especially fatty foods.
M. Fukuda
semanticscholar   +1 more source

Medial Temporal Lobe Subregional Atrophy in Aging and Alzheimer's Disease: A Longitudinal Study

Frontiers in Aging Neuroscience, 2021
Medial temporal lobe (MTL) atrophy is a key feature of Alzheimer's disease (AD), however, it also occurs in typical aging. To enhance the clinical utility of this biomarker, we need to better understand the differential effects of age and AD by ...
Léa Chauveau, Elizabeth Kuhn, Cassandre Palix, Francesca Felisatti, Valentin Ourry, Valentin Ourry, Vincent de La Sayette, Gaël Chételat, Robin de Flores   +8 more
doaj   +1 more source

Tirzepatide: A Novel, Once-weekly Dual GIP and GLP-1 Receptor Agonist for the Treatment of Type 2 Diabetes

touchREVIEWS in Endocrinology, 2022
Gastrointestinal hormones are currently used to treat type 2 diabetes mellitus (T2D). Incretin preparations with gastric inhibitory polypeptide (GIP) activity or glucagon-like peptide-1 (GLP-1) provide new means for controlling blood glucose levels, body
Shizuka Kaneko
semanticscholar   +1 more source

GIP as a Therapeutic Target in Diabetes and Obesity: Insight From Incretin Co-agonists

Journal of Clinical Endocrinology and Metabolism, 2020
The 2 hormones responsible for the amplification of insulin secretion after oral as opposed to intravenous nutrient administration are the gut peptides, glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP).
J. Holst, M. Rosenkilde
semanticscholar   +1 more source

The Role of GIP in the Regulation of GLP-1 Satiety and Nausea

Diabetes, 2021
Gastric inhibitory peptide (GIP) is best known for its role as an incretin hormone in control of blood glucose concentrations. As a classic satiation signal, however, the literature illustrates a mixed picture of GIP involvement with an at best weak ...
M. R. Hayes, T. Borner, B. D. De Jonghe
semanticscholar   +1 more source

Gluten Immunogenic Peptides (GIP) Point-of-Care Urine Test in Coeliac Disease Follow-up before and during the COVID-19 Lockdown in Italy

Clinical and Experimental Gastroenterology, 2021
Carolina Ciacci,1 Mario Gagliardi,1 Monica Siniscalchi,1 Monica Ruotolo,1 Antonella Santonicola,1 Najla Hajji,1 Fabiana Zingone2 1Celiac Center at Department of Medicine, Surgery, and Dentistry, Scuola Medica Salernitana, University of Salerno, Salerno ...
Ciacci C, Gagliardi M, Siniscalchi M, Ruotolo M, Santonicola A, Hajji N, Zingone F   +6 more
doaj  

Effects of GLP-1 receptor agonists and dual incretin agonists on adipocyte type and size [PDF]

Exploration of Endocrine and Metabolic Diseases
Glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1RAs) and dual incretin agonists have demonstrated significant potential in improving adipose tissue function beyond their established effects on appetite suppression and weight loss.
Nino Turashvili
doaj   +1 more source

LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept

Molecular Metabolism, 2018
Objective A novel dual GIP and GLP-1 receptor agonist, LY3298176, was developed to determine whether the metabolic action of GIP adds to the established clinical benefits of selective GLP-1 receptor agonists in type 2 diabetes mellitus (T2DM).
T. Coskun, K. Sloop, C. Loghin, Jorge Alsina-Fernandez, S. Urva, K. Bokvist, Xuewei Cui, Daniel A. Briere, Over Cabrera, W. Roell, U. Kuchibhotla, J. Moyers, C. Benson, R. Gimeno, D. D’Alessio, A. Haupt   +15 more
semanticscholar   +1 more source

Effects of Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide on Biomarkers of Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes

Diabetes Care, 2020
OBJECTIVE To determine the effect of tirzepatide, a dual agonist of glucose-dependent insulinotropic polypeptide and glucagon-like peptide 1 receptors, on biomarkers of nonalcoholic steatohepatitis (NASH) and fibrosis in patients with type 2 diabetes ...
M. Hartman, A. Sanyal, R. Loomba, J. Wilson, Amir Nikooienejad, R. Bray, C. Karanikas, K. Duffin, D. Robins, A. Haupt   +9 more
semanticscholar   +1 more source

Loss of KDM1A in GIP-dependent primary bilateral macronodular adrenal hyperplasia with Cushing's syndrome: a multicentre, retrospective, cohort study.

The Lancet Diabetes and Endocrinology, 2021
BACKGROUND GIP-dependent primary bilateral macronodular adrenal hyperplasia with Cushing's syndrome is caused by aberrant expression of the GIP receptor in adrenal lesions. The bilateral nature of this disease suggests germline genetic predisposition. We
Fanny Chasseloup, I. Bourdeau, A. Tabarin, D. Regazzo, C. Dumontet, Nataly Ladurelle, L. Tosca, L. Amazit, A. Proust, R. Scharfmann, Tiphaine Mignot, F. Fiore, S. Tsagarakis, D. Vassiliadi, D. Maiter, Jacques Young, A. Lecoq, Vianney Deméocq, S. Salenave, H. Lefebvre, L. Cloix, P. Emy, Rachel Dessailloud, D. Vezzosi, C. Scaroni, M. Barbot, W. D. de Herder, F. Pattou, M. Tetreault, G. Corbeil, M. Dupeux, B. Lambert, G. Tachdjian, A. Guiochon‐Mantel, I. Beau, P. Chanson, S. Viengchareun, A. Lacroix, J. Bouligand, P. Kamenickỷ   +39 more
semanticscholar   +1 more source